BCL-X<sub>L</sub> PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRAS<sup>G12C</sup>-mutated cancers

Sajid Khan<sup>1</sup>*, Janet Wiegand<sup>1</sup>, Peiyi Zhang<sup>2</sup>, Wanyi Hu<sup>2</sup>, Dinesh Thummuri<sup>1</sup>, Vivekananda Budamagunta<sup>1,3,4</sup>, Nan Hua<sup>1</sup>, Lingtao Jin<sup>5</sup>, Carmen J. Allegra<sup>6</sup>, Scott E. Kopetz<sup>7</sup>, Maria Zajac-Kaye<sup>5</sup>, Frederic J. Kaye<sup>6</sup>, Guangrong Zheng<sup>2</sup> and Daohong Zhou<sup>1</sup>*

**Abstract**

KRAS mutations are the most common oncogenic drivers. Sotorasib (AMG510), a covalent inhibitor of KRAS<sup>G12C</sup>, was recently approved for the treatment of KRAS<sup>G12C</sup>-mutated non-small cell lung cancer (NSCLC). However, the efficacy of sotorasib and other KRAS<sup>G12C</sup> inhibitors is limited by intrinsic resistance in colorectal cancer (CRC) and by the rapid emergence of acquired resistance in all treated tumors. Therefore, there is an urgent need to develop novel combination therapies to overcome sotorasib resistance and to maximize its efficacy. We assessed the effect of sotorasib alone or in combination with DT2216 (a clinical-stage BCL-X<sub>L</sub> proteolysis targeting chimera [PROTAC]) on KRAS<sup>G12C</sup>-mutated NSCLC, CRC and pancreatic cancer (PC) cell lines using MTS cell viability, colony formation and Annexin-V/PI apoptosis assays. Furthermore, the therapeutic efficacy of sotorasib alone and in combination with DT2216 was evaluated in vivo using different tumor xenograft models. We observed heterogeneous responses to sotorasib alone, whereas its combination with DT2216 strongly inhibited viability of KRAS<sup>G12C</sup> tumor cell lines that partially responded to sotorasib treatment. Mechanistically, sotorasib treatment led to stabilization of BIM and co-treatment with DT2216 inhibited sotorasib-induced BCL-X<sub>L</sub>/BIM interaction leading to enhanced apoptosis in KRAS<sup>G12C</sup> tumor cell lines. Furthermore, DT2216 co-treatment significantly improved the antitumor efficacy of sotorasib in vivo. Collectively, our findings suggest that due to cytostatic activity, the efficacy of sotorasib is limited, and therefore, its combination with a pro-apoptotic agent, i.e., DT2216, shows synergistic responses and can potentially overcome resistance.

**Keywords:** KRAS<sup>G12C</sup>, BCL-X<sub>L</sub>, PROTAC, Sotorasib, Drug resistance

To the Editor,

KRAS mutations are the most common drivers in non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and pancreatic cancer (PC) [1]. While KRAS<sup>G12C</sup> inhibitors including sotorasib have shown tumor responses in a subset of NSCLC, there was reduced activity in CRC patients. To enhance its efficacy, sotorasib has been evaluated in preclinical studies using different combinations [2–4]. These combinations, however, are mostly cytostatic, limiting the potential for clinical benefit.

BCL-X<sub>L</sub> is an anti-apoptotic protein that belongs to the BCL-2 family and is an important therapeutic target in multiple cancers. However, targeting BCL-X<sub>L</sub> with conventional inhibitors causes severe thrombocytopenia, limiting their clinical use [5–7]. Recently, our group has reported platelet-sparing targeting of BCL-X<sub>L</sub> by proteolysis targeting chimeras (PROTACs) exemplified by DT2216. DT2216 has shown promising antitumor activities in BCL-X<sub>L</sub>-dependent hematologic cancers as a
single agent therapy and in multiple solid tumors when combined with conventional chemotherapy [8–10]. Here, we hypothesize that combining sotorasib with DT2216 could be safer and synergistic, because BCL-X_L is overexpressed in KRAS-mutated tumors [11].

We found that 1 µM of DT2216 can completely deplete BCL-X_L in different KRAS<sup>G12C</sup>-mutated cancer cell lines (Additional file 1: Fig. 1a-d); therefore, we used this concentration for in vitro experiments. In our study, sotorasib showed heterogeneous effects against KRAS<sup>G12C</sup>-mutated cancer cell lines (Fig. 1a; Additional file 1: Fig. 2a). Moreover, sotorasib caused only partial reduction in viability in the sensitive cell lines (referred to as partially sensitive cell lines). Interestingly, a combination of sotorasib and DT2216 synergistically reduced viability of partially sensitive cell lines, as well as enhanced inhibition of colony formation and apoptosis induction compared to sotorasib monotherapy (Fig. 1a–d). We further evaluated whether or not the inhibition of other BCL-2 anti-apoptotic proteins could enhance the efficacy of sotorasib. We found that the inhibition of BCL-X_L, but not BCL-2 or MCL-1, can sensitize all the three partially sensitive cell lines to sotorasib treatment (Additional file 1: Fig. 2b). Moreover, non-KRAS<sup>G12C</sup>-mutated cell lines did not respond to sotorasib treatment alone as well as in combination with DT2216 (Additional file 1: Fig. 2c).

Fig. 1. A combination of sotorasib and DT2216 has synergistic antitumor activity through suppression of BCL-X_L/BIM interaction in KRAS<sup>G12C</sup>-mutated cancer cell lines. a Viability of KRAS<sup>G12C</sup>-mutated H358 NSCLC, MIA PaCa-2 PC and SW837 CRC cell lines after they were treated with increasing concentrations of sotorasib (Sot) in threefold increments with either DMSO or DT2216 (DT, 1 µM) for 72 h. The data are presented as percentage viability relative to control (mean ± SD; n = 6 replicate cell cultures) as measured by MTS assay. b CDI values were calculated at different concentrations of Sot used in combination with 1 µM of DT, and their averages are shown in the table for H358, MIA PaCa-2 and SW837 cell lines. CDI < 0.7 indicates significant synergistic effect. CDI < 1 indicates synergistic effect, CDI = 1 indicates additive effect, and CDI > 1 indicates antagonistic effects. EC<sub>50</sub>, half-maximal effective concentration (equivalent to IC<sub>50</sub> or half-maximal inhibitory concentration); CDI, coefficient of drug interaction. c Colony formation in indicated cell lines after they were treated with DT (1 µM), Sot (0.1 µM), or a combination of the two (Combo) for 10–14 days followed by crystal violet staining. d Apoptosis in the cell lines after they were treated with indicated concentrations of Sot with either DMSO or DT (1 µM) for 48 h (H358) or 72 h (MIA PaCa-2 and SW837). The data are presented as percentage Annexin V<sup>+</sup> (apoptotic) cells in total cell population (mean ± SEM) as measured by Annexin V/PI staining using flow cytometry. Statistical significance was determined by one-way ANOVA and Tukey’s multiple comparison test. *p < 0.05, **p < 0.01, ***p < 0.001. ns, not significant. e–g Immunoblot analysis of BCL-X_L, BIM, BMF and PUMA in H358 (e), MIA PaCa-2 (f) and SW837 (g) cell lines after they were treated with indicated concentrations of Sot with either DMSO or DT (1 µM) for 24 h. Immunoblots detect three isoforms of BIM, i.e., short isoform (BIM<sub>s</sub>), long isoform (BIM<sub>l</sub>) and extra-long isoform (BIM<sub>el</sub>). Among them, BIM<sub>el</sub> is the major isoform and is shown here. Densitometry graphs of selected immunoblots normalized to equal loading control β-tubulin are shown in Additional file 1: Fig. 8a–c. h–j Immunoprecipitation analysis of BCL-X_L in H358 (h), MIA PaCa-2 (i) and SW837 (j) cell lines after they were treated with Sot (0.1 µM), DT (1 µM) or Combo for 24 h, and the immunoprecipitated as well as input samples were subjected to immunoblot analysis of BIM, BMF, PUMA and BCL-X_L. β-tubulin was used as an equal loading control.
addition, DT2216 could not synergize with a MEK inhibi-

tion of KRAS signaling (Additional file 1: Fig. 9c). Next, we found that sotorasib 

did not respond to sotorasib monotherapy.

Next, we elucidated the mechanism involved in the 

DT2216 + sotorasib synergistic activity. DT2216 

treatment with sotorasib was not able to enhance or pro-

long the inhibition of KRAS signaling (Additional file 1: 

Fig. 5a-h; Additional file 1: Fig. 6). Therefore, we hypo-

thesized that sotorasib might induce apoptotic priming 

through the stabilization of BH3-only pro-apoptotic 

proteins (e.g., BIM, BMF and PUMA). We observed a 

concentration-dependent upregulation of BIM and BMF 

after sotorasib treatment in all the partially sensitive cell 

lines, while PUMA was also upregulated in MIA PaCa-2 

and SW837 (Fig. 1e–g; Additional file 1: Fig. 7a-d and 

8a-d). Sotorasib or sotorasib + DT2216 had no consid-

erable effect on other BCL-2 proteins (Additional file 1: 

Fig. 7a-d). Further, sotorasib + DT2216 combination 

led to a pronounced increase in cleaved caspase-3 and 

cleaved PARP levels in partially sensitive cell lines indi-

cating apoptosis induction (Additional file 1: Fig. 7a-c). 

We observed a decrease in p-BIM (S69) levels after soto-

rasib treatment (Additional file 1: Fig. 9a, b), which 

might be attributed to BIM stabilization as ERK activation 

is known to induce BIM (S69) phosphorylation and degra-

dation (12). In addition, sotorasib led to a concentration-

dependent upregulation of BCL2L11 (BIM coding gene) 

(Additional file 1: Fig. 9c). Next, we found that sotorasib 

selectively induces BCL-Xl interaction with BIM, which 

was disrupted upon BCL-Xl degradation with DT2216 

(Fig. 1h–j). These results suggest that sotorasib induces 

apoptotic priming that can be exploited by DT2216 to 

induce apoptosis in KRASG12C-mutated cancer cells.
Finally, we investigated the efficacy of sotorasib + DT2216 combination in mouse xenografts. As expected, DT2216 alone had no significant effect on tumor growth. The DT2216 + sotorasib combination led to significant tumor inhibition compared to sotorasib monotherapy (Fig. 2a–f). The combination treatment was quite safe as indicated by no significant change in mouse body weights, as well as no clinically significant decrease in blood cell counts was seen (Additional file 1: Fig. 10a-c; Additional file 1: Fig. 11a, b). We also confirmed BCL-X \(_{l}\) degradation and KRAS engagement with DT2216 and sotorasib treatments, respectively (Fig. 2g–i; Additional file 1: Fig. 12a). In addition, sotorasib-mediated inhibition of ERK was associated with BIM accumulation in MIA PaCa-2 xenograft tumors leading to an increase in cleaved caspase-3 and cleaved PARP in combination-treated tumors (Additional file 1: Fig. 12b, c). Further, IHC staining showed a considerable decrease in Ki67 and a significant increase in cleaved caspase-3 in combination-treated H358 tumors (Additional file 1: Fig. 12d), which was consistent with tumor growth inhibition (Fig. 2a, d).

In conclusion, our studies show that DT2216 enhances the therapeutic efficacy of sotorasib which warrants clinical testing of this combination, particularly in KRAS\(^{G12C}\)-mutated CRC patients who otherwise derive minimal benefit from sotorasib monotherapy.

Abbreviations

NSCLC: Non-small cell lung cancer; CRC: Colorectal cancer; PC: Pancreatic cancer; RTK: Receptor tyrosine kinase; BCL-\(_{XL}\): B-cell lymphoma extra-large; PROTAC: Proteolysis targeting chimera; IHC: Immunohistochemistry.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s13045-022-01241-3.

Additional file 1. Materials and Methods, Supplementary Figures, and Supplementary Table.

Acknowledgements

Not applicable.

Authors’ contributions

S.K. conceived, designed and supervised the study, performed most of the in vitro and in vivo experiments, analyzed and interpreted data, and wrote and revised the manuscript; J.W. and N.H. were involved in some of the in vivo studies; P.Z. and W.H. synthesized and purified DT2216 and prepared the vehicle and formulated DT2216 for the studies; D.T. and V.B. performed some of the in vitro experiments; L.J., C.J.A., S.E.K., M.Z.-K. and F.J.K. provided some of the reagents, revised and commented on the manuscript; G.Z. supervised the synthesis, purification and formulation of DT2216, and revised the manuscript; D.Z. conceived, designed and supervised the study, analyzed and interpreted data, and wrote and revised the manuscript. All authors discussed the results and commented on the manuscript. All authors read and approved the final manuscript.

Funding

This study was supported in part by US National Institutes of Health (NIH) Grant RO1 CA242003 (D.Z. & G.Z.).

Availability of data and materials

All data generated or analyzed during this study are included in this published article or its supplementary information files. The raw datasets are available from the corresponding authors on reasonable request.

Declarations

Ethics approval and consent to participate

All the animal procedures were performed in accordance with the rules of the IACUC at the University of Florida.

Consent for publication

Not applicable.

Competing interests

S.K., P.Z., D.T., G.Z. and D.Z. are inventors of two patent applications for use of BCL-X\(_{L}\), PROTACs as senolytic and antitumor agents. G.Z. and D.Z. are co-founders of and have equity in Dialectic Therapeutics, which develops BCL-\(_{Xl}\)/\(_{L}\) PROTACs to treat cancer.

Author details

1. Department of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL, USA. 2. Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, USA. 3. Department of Neuroscience, College of Medicine, University of Florida, Gainesville, FL, USA. 4. Department of Anatomy and Cell Biology, College of Medicine, University of Florida, Gainesville, FL, USA. 5. Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Received: 5 January 2022 Accepted: 19 February 2022 Published: 9 March 2022

References

1. Moore AR, Rosenberg SC, McCormick F, Malek S. RAS-targeted therapies: Is the undruggable drugged? Nat Rev Drug Discov. 2020;19(5):533–52.
2. Canon J, Rex K, Saiki AF, Mohir C, Cooke K, Bagal D, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019;575(7781):217–23.
3. Ryan MB, Fece de la Cruz F, Phat S, Myers DT, Wong E, Shahzade HA, et al. Vertical pathway inhibition overcomes adaptive feedback resistance to KRAS. Clin Cancer Res. 2020;26(7):1633–43.
4. Misale S, Fatheree JP, Corteo E, Li C, Bilton S, Timonina D, et al. The clinical PROTAC G12C NSCLC models are sensitive to direct targeting of KRAS in combination with PI3K inhibition. Clin Cancer Res. 2019;25(2):796–807.
5. Mason KD, Carpinelli MR, Fletcher JL, Collinge JE, Hiltem AA, Ellis S, et al. Programmed anuclear cell death deems platelet life span. Cell. 2007;128(6):1173–86.
6. Zhang H, Nimmer PM, Tahir SK, Chen J, Fryer RM, Hahn KR, et al. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ. 2007;14(5):943–51.
7. Schoenwaelder SM, Jamran KE, Gardiner EE, Hua M, Qiao J, White MJ, et al. Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopenia that undermines the hemostatic function of platelets. Blood. 2011;118(6):1663–74.
8. Khan S, Zhang X, Lv D, Zhang Q, He Y, Zhang P, et al. A selective BCL-X L PROTAC degrader achieves safe and potent antitumor activity. Nat Med. 2019;25(2):1938–47.
9. He Y, Koch R, Budamagunta V, Zhang P, Zhang X, Khan S, et al. DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas. J Hematol Oncol. 2020;13(1):95.
10. Zhang X, Thummuri D, Liu X, Hu W, Zhang P, Khan S, et al. Discovery of PROTAC BCL‑X L degraders as potent anticancer agents with low on‑
target platelet toxicity. Eur J Med Chem. 2020;192:112186.
11. Kasper S, Breitenbuecher F, Reis H, Brandau S, Worm K, Köhler J, et al. Oncogenic RAS simultaneously protects against anti‑EGFR antibody‑
dependent cellular cytotoxicity and EGFR signaling blockade. Oncogene. 2013;32(23):2873–81.
12. Luciano F, Jacquel A, Colosetti P, Herrant M, Cagnol S, Pages G, et al. Phosphorylation of Bim‑EL by Erk1/2 on serine 69 promotes its degrada‑
tion via the proteasome pathway and regulates its proapoptotic function. Oncogene. 2003;22(43):6785–93.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub‑
lished maps and institutional affiliations.